The Long Road to Healing: Why Sickle Cell Disease Still Demands Better, Accessible Treatments

Every year, when September rolls around, our community pauses to observe Sickle Cell Awareness Month. It’s a crucial time to shed light on a condition that, frankly, has lingered for far too long without the widespread, truly effective treatments its patients desperately need. As someone deeply embedded in this fight, leading the Sickle Cell Foundation of Georgia, I've seen firsthand the resilience of individuals living with sickle cell disease (SCD) – and the often frustratingly slow pace of progress in their care.

It's quite astonishing to think about just how long this disease has been part of the human story. While Western medicine 'officially' identified it in 1904, thanks to Dr. Ernest E. Irons observing a young dental student in Chicago, and Dr. James B. Herrick later describing it in 1910, its roots stretch back hundreds, even thousands, of years. Long before microscopes revealed its distinctive crescent-shaped cells, communities in Africa and the Mediterranean knew of it. Ancient African medical documents, some from as far back as the 1870s, hint at its presence, referring to it in terms like 'ogbanjes' – a haunting term for children who 'come and go,' tragically short-lived. Some families in Ghana can even trace its lineage back to the 17th century. It wasn't until 1949 that scientists pinpointed it as the very first 'molecular disease,' understanding the specific hemoglobin change that causes such profound suffering.

Given this incredibly long history, one would hope for a similarly long list of groundbreaking treatments. But alas, that's simply not the reality. For decades, options were incredibly limited. It wasn't until 1998 that the FDA approved Hydroxyurea, the first drug specifically for SCD. Think about that – nearly a century after its initial Western medical description! The 21st century has brought a trickle of new therapies, which, don't get me wrong, are vital steps forward. We saw the arrival of L-glutamine, an oral amino acid powder, and Crizanlizumab, a monthly IV monoclonal antibody, both in 2017. Then came Voxelotor (Oxbryta) in 2019, offering some hope.

Yet, even these advancements aren't without their complexities. The journey for some of these drugs has been bittersweet, to say the least. Take Voxelotor, for example. After its 2019 approval, it showed promise. But then, just last year in 2024, its maker, Pfizer, voluntarily withdrew it from the market. The reason? Serious safety concerns, leading the FDA to conclude that its benefits no longer outweighed the risks. It’s a stark reminder that the path to effective, safe treatment is often winding and fraught with challenges.

And now, we stand on the cusp of what many are calling a revolution: gene therapies. Casgevy and Lyfgenia, both approved in 2023, are touted as potential cures – a truly monumental leap! The idea of a cure, of eradicating the lifelong pain and complications of sickle cell disease, is almost unfathomable for those who have fought this battle for so long. But here’s the rub, and it’s a big one: these therapies are incredibly complex, staggeringly expensive, and, in their current state, almost inaccessible to the vast majority of patients who could benefit. The financial burden and logistical hurdles are immense, creating a painful irony where a cure exists, yet remains out of reach for so many.

So, as we observe Sickle Cell Awareness Month once more, the message remains clear, and frankly, urgent. We need more than just awareness; we need action. We need continued research, yes, but just as importantly, we need a concerted effort to make promising treatments – and actual cures – affordable and accessible to every single person living with sickle cell disease. Their journey has been long, their resilience extraordinary, and their need for true, equitable care is undeniable. It's high time we truly delivered.